HSPA9 and breast carcinoma: The researchers explained this discrepancy by the inability of mortaparibPlus to disrupt the apoptosis-inducing factor (AIF)–mortalin complexes and suggested the AIF-mediated (i.e., caspase-independent) mechanism of cell death in breast cancer T47D cells [232].